EUVIMEDEUVIMED entdecken
Crossref

Silibinin alleviates inflammation‐induced bone loss by modulating biological interaction between human gingival fibroblasts and monocytes

Ren-Yeong Huang iD, Hua-Yang Chang, Shu-Mi Chih, Thomas Van Dyke, Chia-Dan Cheng, Cheng-En Sung, Pei-Wei Weng, Yi-Shing Shieh, Wan-Chien Cheng

Journal of Periodontology · 2023

DOI: 10.1002/jper.22-0535 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Periodontology, 2023. Verfasst von Ren-Yeong Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Periodontology, School of Dentistry, Tri-Service General Hospital and National Defense Medical Center, Taipei, Taiwan. Hauptthemen laut MEDLINE: Monocytes, Periodontitis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Ministry of National Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Silibinin has shown various pharmacological effects that could be attributed to its antioxidant, anti‐inflammatory, and immunoregulatory properties. However, the therapeutic potential of silibinin for periodontitis has not been investigated.

Methods

The therapeutic effects of silibinin in ligation‐induced experimental periodontitis were investigated using biochemical, histological, and immunohistochemical methods. The effects of silibinin on the osteoclastogenesis of RAW264.7 cells were investigated using TRAP staining, quantitative polymerase chain reaction (qPCR), pit formation, and immunoblotting. Moreover, its effects on inflammatory cytokine production, RANKL expression, and oxidative stress in lipopolysaccharide (LPS)‐stimulated human gingival fibroblasts (HGFs) were evaluated using qPCR and flow cytometry. A coculture system was established to elucidate the effects of silibinin on the crosstalk between LPS‐stimulated HGFs and undifferentiated monocytes.

Results

Silibinin significantly reduced the alveolar bone loss, decreased the gingival inflammation and RANKL expression, and decreased the RANKL/osteoprotegerin ratio in gingival tissues in experimental periodontitis. The in vitro results showed that silibinin inhibited RANKL‐induced osteoclast differentiation and function of RAW264.7 cells and suppressed RANKL‐induced nuclear factor of activated T cells 1 (NFATc1) induction and translocation through the nuclear factor‐κB and mitogen‐activated protein kinase signaling pathways. Silibinin decreased the inflammatory cytokine level and oxidative stress production in LPS‐stimulated HGFs; significantly suppressed membrane‐bound RANKL expression on LPS‐stimulated HGFs; and significantly disrupted TRAP + cell differentiation in the coculture system.

Conclusions

Silibinin effectively inhibits inflammation‐induced bone loss in experimental periodontitis based on the regulation of stimulated HGFs by inhibiting the expression of inflammatory and osteoclastogenic mediators. Collectively, targeting the inflamed HGF resolution that mediates osteogenesis may use silibinin as a potential drug‐repurposing candidate for modulating alveolar bone destruction in periodontitis. Summary Silibinin effectively inhibits inflammation‐induced bone loss in experimental periodontitis based on the regulation of stimulated HGFs by inhibiting the expression of inflammatory and osteoclastogenic mediators.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MonocytesPeriodontitisHumansSilybinLipopolysaccharidesOsteoclastsInflammationCytokinesCell DifferentiationFibroblastsRANK Ligand

Stichwörter der Autor:innen

RANK ligandSilybinfibroblastsinflammationosteoclastsperiodontitis

Substanzen

SilybinLipopolysaccharidesCytokinesRANK Ligand

Autor:innen und Institutionen

  • Department of Periodontology, School of Dentistry, Tri-Service General Hospital and National Defense Medical Center, Taipei, Taiwan.
  • Graduate Institute of Dental Sciences, National Defense Medical Center, Taipei, Taiwan.
  • Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA.
  • Department of Applied Oral Sciences, The Forsyth Institute, Cambridge, Massachusetts, USA.
  • Department of Orthopedics, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
  • Department of Orthopedics, College of Medicine, Taipei Medical University, Taipei, Taiwan.

ORCID-Profile: Ren-Yeong Huang

Förderung

  • Ministry of National Defense

Zitieren

APA

Huang, R. Y., Chang, H. Y., Chih, S. M., Dyke, T. V., Cheng, C. D., Sung, C. E., Weng, P. W., Shieh, Y. S., & Cheng, W. C. (2023). Silibinin alleviates inflammation‐induced bone loss by modulating biological interaction between human gingival fibroblasts and monocytes. Journal of Periodontology. https://doi.org/10.1002/jper.22-0535

Vancouver

Huang RY, Chang HY, Chih SM, Dyke TV, Cheng CD, Sung CE, et al. Silibinin alleviates inflammation‐induced bone loss by modulating biological interaction between human gingival fibroblasts and monocytes. Journal of Periodontology. 2023. doi:10.1002/jper.22-0535

BibTeX
@article{Huang2023,
  author = {Huang, Ren-Yeong and Chang, Hua-Yang and Chih, Shu-Mi and Dyke, Thomas Van and Cheng, Chia-Dan and Sung, Cheng-En and Weng, Pei-Wei and Shieh, Yi-Shing and Cheng, Wan-Chien},
  title = {Silibinin alleviates inflammation‐induced bone loss by modulating biological interaction between human gingival fibroblasts and monocytes},
  journal = {Journal of Periodontology},
  year = {2023},
  doi = {10.1002/jper.22-0535}
}
Kostenlos starten →